Lab Notes is a series from Camel City Women's Wellness dedicated to helping you understand the labs we order, why we order them, and what the results actually tell us, and don't tell us, about your health. Because a number on a page without context is just a number.
What Is FSH?
Follicle-stimulating hormone (aka FSH) is produced by the pituitary gland, a small structure at the base of the brain that serves as a master regulator of the reproductive hormonal system. FSH does exactly what its name suggests: it stimulates the ovarian follicles to develop and mature each month in preparation for ovulation. In a normally menstruating woman, about 30 follicles develop a month - only one of those matures to ovulation. When these follicles develop, this is how the ovary produces estradiol. What a neat little system!
*side note - to be accurate, I will be using the term estradiol instead of estrogen. Estrogen is a group of hormones. Estradiol is a type of estrogen, and the most potent in the female body, and it is the one that is produced by the ovary.
FSH operates within a feedback loop. When the ovaries are functioning normally and producing adequate estradiol, that estradiol signals the pituitary to dial FSH production back down, the ovaries are responding, and the system is in balance. When estradiol levels are low, whether because of menopause, premature ovarian insufficiency, or other causes, the pituitary loses that feedback signal and compensates by producing more and more FSH, essentially sending an increasingly urgent message to ovaries that are no longer responding.
This is why FSH rises during the menopausal transition. The ovaries are producing less estradiol, the feedback loop weakens, and FSH climbs.
What an Elevated FSH Tells Us
An elevated FSH, particularly a level above 25 mIU/mL in the right clinical context, has traditionally been used as a laboratory marker of ovarian insufficiency and the menopausal transition.
In clinical practice, an elevated FSH can support a diagnosis of:
Perimenopause: during which FSH begins to rise, though often erratically. In early perimenopause, FSH may be elevated on one draw and completely normal on another, reflecting the unpredictable hormonal fluctuations of the transition. IMPORTANT: If the FSH is normal it doesn’t mean you are not perimenopausal.
Menopause: defined clinically as 12 consecutive months without a menstrual period, but often supported by a persistently elevated FSH alongside low estradiol in women with an intact uterus.
Premature Ovarian Insufficiency (POI): defined as loss of normal ovarian function before age 40, diagnosed by just one FSH levels above 25 mIU/mL taken, alongside 4-6 months of no period.
FSH can also help distinguish primary ovarian causes of hormonal disruption from secondary causes originating in the pituitary or hypothalamus. In primary ovarian insufficiency, FSH will be high, the pituitary is working hard to stimulate ovaries that aren't responding. In hypothalamic amenorrhea (as seen with extreme exercise, low body weight, or chronic stress), FSH will be low or inappropriately normal, the signal from the brain itself has been suppressed.
Why FSH Is Controversial in the Menopause World
Here is where the clinical nuance becomes important and where the traditional reliance on FSH as a diagnostic tool for menopause has been significantly challenged.
FSH alone does not diagnose menopause. Menopause is a clinical diagnosis, defined by 12 months of amenorrhea in a woman of appropriate age. A single FSH level, even a dramatically elevated one, cannot confirm menopause, and a normal FSH does not rule out perimenopause. It’s best to follow bleeding patterns, symptom constellations, and the whole clinical picture.
FSH is highly variable during perimenopause. This is the core problem. During the perimenopausal transition, FSH fluctuates significantly, sometimes day to day, sometimes cycle to cycle. A woman in early perimenopause can have an FSH of 45 mIU/mL one month and 12 mIU/mL the next. Drawing a single FSH and using it to make definitive clinical decisions is unreliable during the very window when women are most symptomatic and most likely to be seeking answers.
FSH does not tell us how symptomatic a woman will be. Some women with markedly elevated FSH have mild symptoms; others with only modestly elevated levels are profoundly impacted. FSH reflects ovarian activity, not symptom burden, not hormonal impact on the brain, and not a woman's quality of life.
FSH cannot (reliably) be used to guide or adjust hormone therapy. This is a critical and frequently misunderstood point. Once a woman is on hormone therapy, her FSH level is not a reliable indicator of whether her treatment is adequate. Exogenous estrogens will suppress FSH through the same feedback mechanism, but a suppressed FSH on treatment does not confirm therapeutic estradiol levels, symptom control, or tissue adequacy. As we discussed in our Journal Club review of the Glynne et al. 2025 study, serum estradiol is the marker that tells us whether the dose is reaching the bloodstream in therapeutic concentrations.
The Menopause Society and most expert guidelines now advise against routine FSH testing to diagnose menopause in women over 45 with classic symptoms, and explicitly state that FSH should not be used to titrate hormone therapy doses.
So why do we still check it? Because in specific clinical contexts, FSH remains genuinely useful, ruling out other causes of menstrual irregularity, evaluating younger women for premature ovarian insufficiency, and providing additional clinical context when the picture is ambiguous.
What We Are Learning: Research From CCWW
At Camel City Women's Wellness, we are not just asking questions about FSH in clinical practice. We are contributing to the evidence base.
We recently wrapped up data collection on a pilot study conducted in partnership with Mira, a hormonal health technology company whose at-home hormone monitoring device tracks FSH, and other hormones, through urine across the cycle or menopausal transition. This was a feasibility study, and while the initial results are still pending evaluation, we plan to continue to contribute in this space.
This work matters because the questions around FSH monitoring, when to check it, what it tells us, and whether at-home longitudinal tracking might offer something that a single clinic draw cannot, are exactly the right questions to be asking right now. We look forward to sharing more as the data are analyzed.
The Bottom Line
FSH is a real and useful hormone marker, but it is not the menopause test it has long been treated as. It is most valuable in specific diagnostic contexts, least valuable as a standalone number used to confirm menopause or guide treatment, and most misused when it substitutes for a thorough clinical conversation.
At CCWW, we check FSH when it adds meaningful information to the clinical picture, and we are equally clear with our patients about what it cannot tell us. Because understanding a lab result includes understanding its limits.
Lab Notes is an educational series from Camel City Women's Wellness. These posts are for educational purposes only and are not a substitute for individualized clinical evaluation. If you have questions about your own lab results, please reach out directly.
